Pancreatic Cancer: Symptoms, Causes, Treatment & Nursing Care

Pancreatic cancer most often means pancreatic ductal adenocarcinoma arising from the pancreatic duct epithelium—a desmoplastic tumour that invades locally into the superior mesenteric vessels, bile duct, duodenum, and adjacent lymph nodes while metastasising early to liver, peritoneum, and lung in many patients. Rarer histologies and pancreatic neuroendocrine tumours follow different natural histories; when clinical teams say “pancreatic cancer” on a general ward they are usually referring to PDAC until histology states otherwise.

Pathophysiology is dominated by dense stroma, poor perfusion, and frequently KRAS-driven signalling, which partly explains resistance to therapy and why small tumours can already harbour micrometastatic disease. The head of the pancreas is the most common site, producing painless obstructive jaundice by compressing the intrapancreatic bile duct; body and tail lesions may present later with pain, nausea, and cachexia without early jaundice. Multidisciplinary teams integrate oncologists, HPB surgeons, gastroenterologists, radiologists, and specialist nurses because margin-negative resection, effective systemic therapy, and meticulous supportive care all influence length and quality of survival.

UICC/AJCC TNM stage (T depth, N nodes, M metastases) still labels overall burden, but HPB practice equally emphasises resectability—especially whether the tumour clears named arteries and veins on high-quality cross-sectional imaging. Borderline categories vary slightly between NCCN, ESMO, and regional networks; write down the exact MDT wording (resectable / borderline / locally advanced / metastatic) because it drives neoadjuvant therapy, stent choices, and surgical candidacy.

↔On a small screen, swipe or scroll sideways to see the full table.

SEER reports that only about 15% of pancreatic cancers remain localised at diagnosis and five-year relative survival for localised disease is far higher than for regional or distant disease—yet many patients still present with advanced stage, underscoring the value of timely specialist referral.

Because the pancreas sits deep in the retroperitoneum, small tumours may evade detection until they obstruct the bile duct, invade the coeliac plexus, or metastasise. Painless progressive jaundice with concentrated urine and pale stools remains a classic pancreatic head presentation, but absence of pain does not imply benign disease.

Typical clusters

• Obstructive jaundice pattern with dark urine, pale stools, and generalized pruritus from bile salt deposition.
• Anorexia, early satiety, and profound cachexia out of proportion to visible tumour burden.
• Insidious epigastric/back radiation pain worsening when supine (coeliac plexus involvement).
• New or sudden-onset type 2 diabetes mellitus in a thin older adult—may herald malignancy.

Atypical or delayed cues

• Isolated nausea and gastric outlet–type vomiting without initial jaundice (pancreatic head or duodenal invasion).
• Acute pancreatitis as the first manifestation when duct obstruction precipitates enzyme activation.
• Silent hepatic capsular stretch from liver metastases or non-specific fatigue before imaging.

Pancreatic cancer is fundamentally a genetic disease at the cellular level superimposed on environmental and heritable risk, yet most patients have no identifiable germline mutation. Risk stratification helps target surveillance discussion for families with cancer syndromes.

Major non-modifiable contributors

• Age—median diagnosis ~71 years in US registry data.
• Family history of pancreatic cancer or hereditary breast/ovarian pathways involving BRCA2, PALB2, ATM, or Lynch genes in selected pedigrees.
• Hereditary pancreatitis and cystic precursor syndromes requiring MDT surveillance.

Modifiable / clinical context

• Tobacco—strongest controllable exposure; stopping smoking remains worthwhile even after diagnosis for overall outcomes.
• Chronic pancreatitis from alcohol or other aetiologies elevates risk through recurrent DNA injury.
• Long-standing insulin resistance and adiposity cluster with PDAC incidence.

Diagnosis confirms malignancy-type, quantifies local vascular involvement, and screens for distant disease so the MDT can classify resectability before committing to surgery.

Clinical assessment

• Review cholestatic symptoms, stool colour, alcohol use, and thromboembolic events (migratory thrombophlebitis can accompany adenocarcinoma).
• Quantify pain with a standardised tool and map radiation patterns; document performance status scores used by oncology.
• Compare baseline and interval waist circumference and stool habits after biliary stenting.

Laboratory investigations

• Liver function tests and clotting when obstructive jaundice present; watch for rapid bilirubin fall after drainage versus stagnation suggesting failed stent.
• Serum CA 19-9: trend after diagnosis but interpret with caution during active cholangitis, Lewis-null phenotype, or incomplete drainage.
• Baseline renal panel before contrast studies and nephrotoxic agents.

Imaging & tissue acquisition

• Multiphase CT of chest and abdomen—cornerstone for staging and vascular mapping.
• MRI/MRCP when biliary anatomy or cystic components remain unclear after CT.
• Endoscopic ultrasound (EUS) with fine-needle aspiration/core when tissue needed prior to neoadjuvant therapy—coordinate peri-procedure anticoagulation holds.
• Initial biliary decompression via ERCP/ upper endoscopy-directed stent or percutaneous transhepatic route when anatomy demands.
• Bedside abdominal ultrasound is rarely sufficient alone for pancreatic mass staging but may support gallbladder assessment.

Diagnostic classification in practice

Rather than relying on a single score, teams synthesise TNM stage, NCCN/ESMO-style resectability, histologic grade, serum marker kinetics, and patient fitness—document the MDT minute summary in the chart so nursing and allied staff align messages with the agreed intent (curative vs palliative).

1. Suspected pancreatic bile duct obstruction: urgent labs, cross-sectional imaging, consider ERCP vs percutaneous drainage per HPB plan; start antibiotics if cholangitis.
2. Metastatic survey: complete CT or MRI chest/abdomen/pelvis; add PET-CT only when equipoise about occult metastases remains.
3. Resectable disease: fitness optimisation, nutritional prehabilitation, glucose control, then surgery ± protocol-based adjuvant gemcitabine or multi-agent chemotherapy depending on trial data and tolerance.
4. Borderline / locally advanced: neoadjuvant gemcitabine-based or intensive regimens (e.g., FOLFIRINOX with dose modifications) ± radiation per protocol; restage before surgery.
5. Metastatic: first-line combination systemic therapy stratified by comorbidity, bilirubin clearance, and patient goals; integrate early palliative care.
6. Treatment failure: radiologic progression or rising symptoms triggers regimen change—only oncology adjusts protocol.

↔On a small screen, swipe or scroll sideways to see the full table.

Therapy must never be nurse-initiated; the sections below describe themes so you can anticipate monitoring burdens and patient questions.

Curative-intent surgery

Pancreaticoduodenectomy (Whipple), distal pancreatectomy, or total pancreatectomy selected by tumour location; arterial resections remain highly specialised. Expect diabetes or worsened glucose control after substantial parenchymal loss.

Systemic chemotherapy (typical building blocks)

• Gemcitabine monotherapy or paired with nab-paclitaxel—common backbone in metastatic and some adjuvant protocols.
• FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) for fit patients—higher efficacy but neuropathy, diarrhoea, and cytopenia burdens.
• Capecitabine-, cisplatin-, or radiation-containing trials for borderline disease—verify trial name and visit schedule.
• Fluorouracil continuous infusion regimens demand pump safety checks and line patency vigilance.

Biliary & supportive measures

• Metal or plastic biliary stents relieve pruritus and enable chemotherapy once bilirubin improves—teach fever as stent occlusion warning.
• Pancreatic enzyme replacement for exocrine insufficiency; coordinate timing with meals per pharmacy.
• Analgesia escalating from NSAIDs (if permitted) to morphine or other opioids with bowel regimens.
• Ondansetron and protocolised antiemetics during infusions administered via intravenous medication pathways.

• Pre-chemotherapy: Verify bilirubin under protocol threshold, CBC and renal profile cleared, antiemetics prescribed, and hydration orders for cisplatin-containing days.
• During cycles: Monitor neuropathy (especially oxaliplatin), diarrhoea volume, oral intake, and oral mucosa—grade toxicities per CTCAE guidance when your service documents them.
• Postoperative pancreaticoduodenectomy: Hourly early drains if policy dictates; measure amylase in drain fluid when ordered; correlate pain with haemoglobin and resting tachycardia.
• Follow-up intervals: CA 19-9 and CT cadence come from the MDT letter—reinforce dates with patients before discharge.
• Escalation triggers: Unexplained fever after stent, bilirubin rebound, inability to tolerate oral analgesia, or new-onset confusion with rising ammonia.

Local / oncologic: portal hypertension from splenic vein thrombosis, duodenal fistula, splenic infarction. Postoperative: pancreatic fistula, delayed gastric emptying, haemorrhage, intra-abdominal abscess. Biliary: stent occlusion, ascending cholangitis. Systemic therapy: febrile neutropenia, mucositis, diarrhoea, neuropathy, tubulopathy with cisplatin, hypersensitivity with taxanes. Thromboembolic: splanchnic or lower-extremity VTE—many patients receive prophylactic anticoagulation per protocol.

No population screening test matches colon or cervical cancer programmes for average-risk adults; prevention therefore focuses on tobacco cessation, weight optimisation, limiting heavy alcohol, and—for high-risk kindreds—enrolling in specialist surveillance with MRI/EUS cadences defined by genetics teams. Promptly investigate new diabetes or pancreatitis episodes in at-risk families.

Population data show modest improvements over decades, yet PDAC still carries among the lowest all-stage survival rates of common cancers because most patients present with advanced disease. Completing multimodal therapy when tolerated, maintaining nutrition, and controlling biliary sepsis can prolong meaningful function even when cure is not realistic—communicate goals transparently and involve specialist nursing services early.

Translate “I feel itchier at night” into recorded bilirubin trends and jaundice assessment scores; translate “I cannot finish meals” into calorie counts and dietitian referral rather than dismissing as anxiety. Patients may minimise pain to remain independent—watch gait, sleep quality, and opioid gaps. When delivering bad news is not your role, you still clarify next-step logistics: stent checks, chemotherapy class times, and emergency contact numbers.

• Strict glucose monitoring after pancreatic resection or high-dose steroids.
• Stool colour and urine colour nursing documentation while jaundice resolves.
• Drain output colour, volume, and odour with specimen labels for amylase when requested.
• Intake/output balance during IV hydration or sepsis care.
• Weekly weights during out-patient chemotherapy cycles.

• Fever, rigors, or hypotension with jaundice—presume cholangitis and mobilise the sepsis pathway.
• Severe unrelenting abdominal pain, haematemesis, or coffee-ground aspirate after pancreatic anastomosis.
• Neurologic change with hypoglycaemia or hyperglycaemia after near-total pancreatectomy.
• Febrile neutropenia during gemcitabine-based or FOLFIRINOX cycles per local definition.

Ward triggers: NEWS rise, new oxygen requirement, glucose <4 mmol/L or >20 mmol/L with ketosis symptoms, drain output > protocol thresholds, bilirubin climbing after prior fall. Actions: repeat labs including venous gas if shocked, withhold oral intake if perforation suspected, obtain urgent HPB or surgical review, alert critical care early for vasopressor need.

Pre-treatment education

• Explain how gemcitabine might affect energy, appetite, and blood counts; reinforce when to call the hotline.
• Teach stent dysfunction cues: return of dark urine, pale stools, or fever.

Perioperative & line care

• Coordinate ERCP preparation per endoscopy unit (fasting, warfarin/DOAC holds per pharmacist plan).
• Keep central venous access bundles sterile; scrub hubs before each chemotherapy administration.

Evaluation

• Use PRO instruments or simple 0–10 appetite scores to objectify nutrition between dietitian visits.

Nursing-priority lens (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. These NCLEX-style clinical judgment practice items pair an unfolding pancreatic cancer case with Priority-FIRST triage, multi-select hepatobiliary escalation cues, deterioration trends during chemotherapy, oncology handover sequencing, staged HPB workflows, pathway matrix picks, and a teaching cloze on biliary red flags.